Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Bigelow Investment Advisors LLC

Bigelow Investment Advisors LLC trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,213 shares of the medical research company’s stock after selling 30 shares during the quarter. Bigelow Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,175,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Beaumont Financial Advisors LLC increased its position in Thermo Fisher Scientific by 1.5% in the 4th quarter. Beaumont Financial Advisors LLC now owns 2,182 shares of the medical research company’s stock valued at $1,158,000 after acquiring an additional 33 shares during the period. Ninepoint Partners LP boosted its stake in Thermo Fisher Scientific by 9.7% during the 4th quarter. Ninepoint Partners LP now owns 1,327 shares of the medical research company’s stock valued at $704,000 after purchasing an additional 117 shares in the last quarter. Davidson Trust Co. boosted its stake in Thermo Fisher Scientific by 10.8% during the 4th quarter. Davidson Trust Co. now owns 1,122 shares of the medical research company’s stock valued at $596,000 after purchasing an additional 109 shares in the last quarter. HTLF Bank bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $782,000. Finally, Fidelis Capital Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 8.9% during the 4th quarter. Fidelis Capital Partners LLC now owns 3,139 shares of the medical research company’s stock worth $1,666,000 after acquiring an additional 256 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $3.26 during trading on Friday, reaching $544.78. 1,738,308 shares of the company traded hands, compared to its average volume of 1,549,863. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The stock’s 50 day moving average price is $571.39 and its two-hundred day moving average price is $527.11. The company has a market cap of $207.95 billion, a price-to-earnings ratio of 35.21, a P/E/G ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $5.40 earnings per share. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. Royal Bank of Canada raised their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. HSBC raised their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Raymond James lifted their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Finally, Evercore ISI lifted their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $604.69.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.